Low frequency or TEL-AML1 In relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup

被引：78

作者：

Rubnitz, JE

Behm, FG

Wichlan, D

Ryan, C

Sandlund, JT

Ribeiro, RC

Rivera, GK

Hancock, ML

Relling, MV

Evans, WE

Pui, CH

Downing, JR

机构：

[1] St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA

[2] St Jude Childrens Res Hosp, Dept Pathol & Lab Med, Memphis, TN 38105 USA

[3] St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA

[4] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA

[5] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA

[6] Univ Tennessee, Coll Med, Dept Pediat, Memphis, TN USA

[7] Univ Tennessee, Coll Med, Dept Pathol, Memphis, TN USA

[8] Univ Tennessee, Coll Med, Dept Pharm, Memphis, TN USA

来源：

LEUKEMIA | 1999年 / 13卷 / 01期

关键词：

TEL-AML1; leukemia; relapse;

D O I：

10.1038/sj.leu.2401257

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The long-term outcome of children with TEL-AML1-positive acute lymphoblastic leukemia (ALL) is uncertain. Although studies of newly diagnosed cases have indicated that the TEL-AML1 fusion confers a favorable prognosis, analyses of relapsed cases have suggested that this may not be true. Because of treatment implications for this subgroup of patients, we have now analyzed 49 cases of relapsed ALL for the presence of TEL-AML1. Only 10% of these cases expressed the fusion, compared to 20-25% of newly diagnosed ALL cases. Additional follow-up of the cohort of 48 newly diagnosed patients with the TEL-AML I fusion previously reported showed that the 10-year cumulative risk of relapse was 9 +/- 5% (s.e.). Together, these results suggest an excellent outcome for TEL-AML1-positive ALL.

引用

页码：19 / 21

页数：3

共 18 条

[1] Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials [J].